A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.

SARS-CoV-2 Clinical Trial

Official title:

A Phase-1, Open-Label, Placebo-Controlled Evaluation of a Live, Recombinant Newcastle Disease Virus Expressing the Spike Protein of SARS-CoV-2 (NDV-HXP-S), an Investigational Product for Intranasal (IN) and/or Intramuscular (IM) Vaccination in Healthy Adults Previously Immunized Against COVID-19.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05181709
• Other study ID #: STUDY-21-01589
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: February 9, 2022
• Est. completion date: April 2024

Study information

• Verified date: April 2024
• Source: Icahn School of Medicine at Mount Sinai
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will be a phase-1, open-label, placebo-controlled, evaluation of two-dosages of a live, recombinant Newcastle disease virus expressing the spike protein of SARS-CoV-2 (NDV-HXP-S), an investigational product for IN, IM, or a combined IN+IM vaccination in healthy adults previously immunized against COVID-19. The IN and IM live virus vaccinations will be identical in composition and only differ in route of administration.

Description:

Primary Study Objective: To evaluate the safety and tolerability profile of two dose levels of the NDV-HXP-S vaccine as an IN, IM, or a combined administration IN+IM to healthy, previously immunized adults up to 14 days after administration.

Secondary Study Objective: To evaluate the safety and tolerability profile of two dose levels of the NDV-HXP-S vaccine as an IN, IM, or a combined administration IN+IM to healthy, previously immunized adults up to 365 days after administration.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 35
• Est. completion date: April 2024
• Est. primary completion date: May 3, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 59 Years

Eligibility

Inclusion Criteria:

1. Willing and able to provide written informed consent prior to performing study procedures.

2. Males and non-pregnant females who are between 18 to 59 years of age.

3. Asymptomatic, RT-PCR negative (at screening) AND without a known prior history of COVID-19 infection (requiring a negative SARS-CoV-2 nucleocapsid antibody test result at screening).

4. Provides documentation showing completion of an FDA authorized or approved COVID-19 vaccination regimen, where the last administration was = 6 months (180 days) from the study enrollment date.

5. IF FEMALE PARTICIPANT: A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

• Is not a woman of child-bearing potential (WOCBP); OR

• Is a WOCBP and using an acceptable contraceptive method during the intervention period (for a minimum of 90 days after NDV-HXP-S vaccination). The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. Only highly effective methods of contraception that have a low user dependency or a combination of highly effective methods that are user dependent may be used.

6. IF MALE PARTICIPANT: Agrees to the following requirements during the intervention period and for at least 90 days after NDV-HXP-S vaccination, which corresponds to the time needed to eliminate reproductive safety risk of the study intervention(s):

• Refrain from donating sperm AND be abstinent from heterosexual intercourse with a female of childbearing potential as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent; OR

• Must agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person. In addition to male condom use, a highly effective method of contraception may be considered in WOCBP partners of male participants.

7. Participant understands and agrees to comply with planned study procedures.

8. Participant agrees to not participate in another clinical trial for treatment of COVID-19 or SARS-CoV-2 through Day 365.

9. Participant agrees to not receive any other vaccination (including COVID-19 vaccines) through day 56 of the study.

10. Provides consent for release of information for hospitalization records and other medically attended visits during the study.

Exclusion Criteria:

1. Clinical and/or laboratory evidence indicative of COVID-19 infection.

2. Demonstrates a STRONG COVID-19 positive antibody serology (>12500 AU/ml per chemiluminescent microparticle immunoassay (including AdviseDx SARS-CoV-2 IgG II)) or a NEGATIVE COVID-19 serology on screening against SARS-CoV-2 spike protein.

3. History of hypersensitivity to egg products.

4. History of severe reactions to vaccinations.

5. Potential for prior NDV exposures (i.e., experience as a bird-handler, poultry farmer, or scientist conducting research with NDV).

6. History of an immunocompromising medical condition (such as primary immunodeficiencies, AIDS, or neutropenia).

7. Current or recent use of immunosuppressive medications (i.e., any systemic corticosteroids, chemotherapeutics, immunoglobulin therapies, etc.) based on the assessment of their half-life by the investigator.

8. Any history of HIV, hepatitis C, hepatitis B (by laboratory testing and/or history), Guillain-Barré syndrome, and/or recent receipt of immunoglobulins and/or blood products.

9. Pregnancy or actively breastfeeding.

10. Other medical condition or abnormal laboratory values which may place participant at increased risk for harm due to participation in the study as determined by the investigator.

11. In the opinion of the investigator that it would be unwise to allow the participant to be randomized into the study, including those persons who the investigator would consider as high risk of SARS-CoV-2 exposure, including healthcare workers with direct patient care and laboratory workers who handle SARS-CoV-2.

12. Participants at higher risk of severe COVID-19, as defined by CDC guidance (https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/index.html), where severity of risk and eligibility will be determined by the investigator. This guidance includes details regarding older adults, people with specific medical conditions, and pregnant and recently pregnant people.

13. Participants with fever or signs of acute infection, including symptoms that could indicate SARS-CoV-2 infection.

14. Participants with a history of chronic rhinitis, nasal septal defect, cleft palate, nasal polyps, or other nasal abnormality that might affect vaccine administration.

15. Participants who prepare food in the food industry and childcare workers who have direct contact with children 5 years of age or younger.

16. Participants who have close or household high-risk contacts including but not limited to:

• Persons more than or equal to 65 years of age

• Children less than or equal to 5 years of age.

• Residents of nursing homes.

• Persons of any age with significant chronic medical conditions as well as immunosuppression or cancer.

Women who are pregnant, trying to become pregnant, or breastfeeding.

17. Participants who are students, post-doctoral candidates, or trainees of the study site, or are members of the research staff.

18. Participants with a history of myocarditis or pericarditis and individuals with an abnormal troponin or abnormal ECG as determined by the investigator. Participants with a screening 12-lead ECG that shows an average QTc interval >500 msec, complete left bundle branch block, ST-T interval changes suggestive of myocardial ischemia, second- or third-degree AV block, or serious bradyarrhythmias or tachyarrhythmias should be excluded from study participation.

Related Conditions & MeSH terms

• COVID-19
• SARS-CoV-2

Intervention

Drug:
• Sodium Chloride
Administered intranasal (IN) and intramuscular (IM) in combination

Biological:
• NDV-HXP-S IN low dose
Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride. Strength: 3.3x108^8 EID50.
• NDV-HXP-S IM low dose
Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride. Strength: 3.3x10^8 EID50.
• NDV-HXP-S IN high dose
Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10^9 EID50.
• NDV-HXP-S IM high dose
Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10^9 EID50.

Locations

Country	Name	City	State
United States	Icahn School of Medicine at Mount Sinai	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Sean Liu

Country where clinical trial is conducted

United States, 

References & Publications (2)

Punnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, Sant Muangnoicharoen, Supitcha Kamolratanakul, Chaisith Sivakorn, Piengthong Narakorn, Somchaiya Surichan, Sumalee Prangpratanporn, Suttida Puksuriwong, Steven Lamola, Laina D Mercer, Rama Raghunandan, Weina Sun, Yonghong Liu, Juan Manuel Carreño, Rami Scharf, Weerapong Phumratanaprapin, Fatima Amanat, Luc Gagnon, Ching-Lin Hsieh, Ruangchai Kaweepornpoj, Sarwat Khan, Manjari Lal, Stephen McCroskery, Jason McLellan, Ignacio Mena, Marcia Meseck, Benjaluck Phonrat, Yupa Sabmee, Ratsamikorn Singchareon, Stefan Slamanig, Nava Suthepakul, Johnstone Tcheou, Narumon Thantamnu, Sompone Theerasurakarn, Steven Tran, Thanakrit Vilasmongkolchai, Jessica A White, Adolfo Garcia-Sastre, Peter Palese, Florian Krammer, Kittisak Poopipatpol, Ponthip Wirachwong, Richard Hjorth, Bruce L Innis. Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial. medRxiv 2021.09.17.21263758; doi: https://doi.org/10.1101/2021.09.17.21263758

Sun W, McCroskery S, Liu WC, Leist SR, Liu Y, Albrecht RA, Slamanig S, Oliva J, Amanat F, Schafer A, Dinnon KH 3rd, Innis BL, Garcia-Sastre A, Krammer F, Baric RS, Palese P. A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines (Basel). 2020 Dec 17;8(4):771. doi: 10.3390/vaccines8040771. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of local and systemic reactions	The safety and tolerability profile assessed by the number of local and systemic reactions.	14 days
Secondary	Number of adverse events (AEs)	The safety and tolerability profile assessed by the number of serious adverse events.	365 days
Secondary	Number of serious adverse events (SAEs)	The safety and tolerability profile assessed by the number of serious adverse events.	365 days
Secondary	Number of medically-attended adverse events (MAAEs)	The safety and tolerability profile assessed by the number of medically-attended adverse events (MAAEs).	365 days

External Links

•   Mount Sinai Develops a Safe, Low-Cost COVID-19 Vaccine That Could Help Low- and Middle-Income Countries